The VJSessions have brought together leading experts virtually to help continue the valuable international collaborations in diseases such as Multiple Myeloma, CLL, AML, Lymphoma, MDS and MPNs. You can view our collection of webinar sessions below at your convenience, as well as being able to listen to podcasts of each session on the go.
Multiple Myeloma
10 Dec 2022
Key highlights from ASH 2022
27 Aug 2022
Updates from IMS 2022
30 Apr 2022
iwCAR-T 2022 day 3 highlights with a focus on myeloma
11 Jun 2022
Myeloma updates from EHA 2022
12 May 2022
Myeloma treatment in the UK
27 Mar 2022
PIKfyve, RAS, the epigenome & PROTAC therapy
26 Mar 2022
Genomics in the age of I-O
26 Mar 2022
Using single-cell analysis to tackle myeloma
26 Mar 2022
Novel targets in 2022
26 Mar 2022
Day 1 highlights from Myeloma 2022
26 Mar 2022
T-Cell engagers
26 Mar 2022
Day 2 highlights from Myeloma 2022
27 Jan 2022
Post-ASH 2021
11 Dec 2021
A deep dive into screening for precursor conditions
20 Jul 2021
Post-EHA/ASCO 2021
08 Jun 2021
The patient perspective
20 May 2021
Post-COMy 2021
13 Jan 2021
Post-ASH 2020 UK
13 Jan 2021
Post-ASH 2020
13 Aug 2020
Myeloma & COVID-19
01 Jul 2020
COMy & EHA 2020
Chronic Lymphocytic Leukemia (CLL)
10 Dec 2022
Key highlights from ASH 2022
29 Sep 2022
Key highlights from SOHO 2022
30 Apr 2022
CLL updates from iwCAR-T 2022
11 Dec 2021
Exploring key ASH 2021 clinical trials in the frontline and R/R setting
26 Jul 2021
Post-EHA/ICML 2021
12 Jan 2021
Post-ASH 2020
03 Aug 2020
ASCO & EHA 2020
Acute Myeloid Leukemia (AML)
16 Sep 2022
iwAL 2022
30 Apr 2022
AML updates from iwCAR-T 2022
11 Dec 2021
Updates in FLT3+ from ASH 2021
06 Jul 2021
Post-EHA/ASCO 2021
14 Jan 2021
Post-ASH 2020
26 Nov 2020
FLT3-Mutated AML
03 Nov 2020
Venetoclax-Based Regimens
21 Oct 2020
IDH Inhibitors
07 Oct 2020
Immunotherapy
16 Jul 2020
EHA & ASCO 2020
Myelodysplastic Syndromes (MDS)
01 Mar 2023
Comparing the ICC and WHO classifications for MDS & their impact on clinical practice
10 Dec 2022
Key highlights from ASH 2022
24 Jun 2022
iwMDS 2022
11 Apr 2022
The impact of AI in MDS
11 Dec 2021
What did ASH 2021 mean for MDS?
05 Jul 2021
Post-EHA/ASCO 2021
11 May 2021
Women in Science
25 Feb 2021
Diagnosis & Prognosis
25 Feb 2021
Giants in MDS
04 Feb 2021
Global Perspectives
20 Jan 2021
Post-ASH 2020
03 Dec 2020
Lower-Risk Disease
12 Nov 2020
Latest Updates
Lymphoma
10 Dec 2022
Key highlights in T-cell lymphoma from ASH 2022
10 Dec 2022
Key highlights in NHL from ASH 2022
10 Sep 2022
iwNHL 2022
18 Aug 2022
Key updates in lymphoma and impact on UK clinical practice
30 Apr 2022
Lymphoma updates from iwCAR-T 2022
03 Apr 2022
CAR-T and lymphoma treatment in the UK
01 Feb 2022
Post-ASH 2021
29 Jul 2021
Post-EHA/ICML 2021
19 Jan 2021
Post-ASH 2020 UK
19 Jan 2021
Post-ASH 2020
General Hematology
30 Apr 2022
Patient focused CAR-T updates
30 Apr 2022
iwCAR-T day 2 highlights
16 Apr 2021
Post-EBMT for Trainees
06 Apr 2021
Post-EBMT
23 Feb 2021
CAR-T & Nursing
22 Jan 2021
Post-ASH 2020
28 Jul 2020
